---

Abstract #

Decision Readiness Index (DRI) is the core metric of the HPF-P framework — a scalar signal summarising the information completeness required before a pharmaceutical portfolio decision can be trusted. Yet a single DRI snapshot provides only a point-in-time view. This article investigates how continuous, real-time monitoring of DRI signals transforms static readiness scores into dynamic control loops. We examine three research questions: (RQ1) what monitoring frequency is required to detect clinically meaningful DRI drift before it escalates into a critical zone; (RQ2) how automated alerting pipelines compare to manual review workflows in response latency and detection accuracy; and (RQ3) which DRI sub-components are most susceptible to silent degradation and how component-level dashboards enable targeted intervention. Original simulation data covering a 90-day pharmaceutical portfolio window are used to derive quantitative thresholds. Our analysis shows that monitoring intervals exceeding 24 hours reduce detection accuracy by more than 8 percentage points and that automated pipelines cut median alert response time from 8.3 hours to 1.4 hours. These findings directly inform the deployment architecture for HPF-P live systems.

1. Introduction #

In the previous article, we established that HPF-P-driven portfolios outperform traditional heuristic and model-based portfolio methods across three benchmark dimensions — net present value stability, decision latency, and robustness under regulatory shock — with a performance advantage of 12–18% measured across 20-scenario Monte Carlo simulations [1]^[2]. Those findings were grounded in retrospective benchmarking. Moving from periodic assessment to continuous operations demands a new infrastructure layer: one that monitors DRI not as a monthly report but as a live telemetry feed.

RQ1: What monitoring cadence (frequency and granularity) is necessary for timely detection of DRI drift events before they reach the critical zone (DRI < 0.45)? RQ2: How do automated alert pipelines compare to manual review processes in terms of detection accuracy and response latency across pharmaceutical portfolio events? RQ3: Which DRI sub-components (data completeness, source timeliness, signal consistency, expert confidence, regulatory alignment) are most prone to silent degradation, and how can component-level monitoring reduce that risk?

Answering these questions is not merely an engineering concern. The pharmaceutical industry operates under tight regulatory timelines where delayed decisions compound risk and cost. Statistical methodology groups in major pharmaceutical organisations now identify decision efficiency as a primary lever for reducing development cycle length [2]^[3]. Quantitative frameworks that can detect readiness degradation before it affects portfolio decisions therefore carry direct economic value.

2. Existing Approaches (2026 State of the Art) #

Continuous monitoring in pharmaceutical portfolio management draws from three distinct traditions: clinical operations monitoring, AI system observability, and statistical process control.

Clinical Operations Monitoring. Project portfolio planning in pharmaceutical R&D has long relied on periodic gate reviews, milestone tracking, and clinical trial performance dashboards [3]^[4]. These systems detect go/no-go conditions at predetermined checkpoints but do not provide inter-milestone signal visibility. A Phase II asset can drift significantly in information quality between quarterly reviews without triggering any alert. The pharmaceutical supply chain literature confirms that digital control-tower approaches — real-time integration of multi-source signals — substantially outperform periodic review in stress scenarios [4]^[5].

AI System Observability. The machine learning engineering community has developed mature frameworks for monitoring model drift, data quality degradation, and prediction confidence decay in production systems [5]^[6]. These include statistical tests (Population Stability Index, Kolmogorov–Smirnov drift detection), sliding window approaches, and threshold-based alerting. The MAESTRO evaluation suite extends these ideas to multi-agent AI systems, tracking reliability and observability metrics continuously [6]^[7]. Medical AI quality assurance frameworks borrow heavily from this tradition, applying continuous monitoring to clinical decision support tools [7]^[8].

Statistical Process Control (SPC) for Pharmaceutical Processes. SPC methods — control charts, CUSUM, EWMA — are regulatory standards in pharmaceutical manufacturing (ICH Q10, FDA PAT guidance). They detect out-of-control signals continuously by comparing observed variation to baseline distributions. The 2026 AI-transformation of pharmaceutical regulatory frameworks explicitly calls for extending SPC concepts to data pipelines and AI decision systems [8]^[9].

flowchart TD
    A[Clinical Gate Reviews] -->|Point-in-time snapshots| L1[Low temporal resolution]
    B[AI Model Observability] -->|Continuous drift detection| S1[Automated telemetry]
    C[Statistical Process Control] -->|Control charts + CUSUM| S2[Statistical thresholding]
    L1 -->|Gap| X[Undetected DRI drift]
    S1 --> R[HPF-P Real-Time Layer]
    S2 --> R
    R --> D[Continuous DRI Signal]

The gap between clinical gate reviews and the continuous observability expected by modern AI portfolio systems creates the deployment challenge this article addresses. No existing framework directly applies SPC-style continuous monitoring to composite DRI scores derived from heterogeneous pharmaceutical data sources.

3. Quality Metrics and Evaluation Framework #

We define three primary metrics to evaluate real-time DRI monitoring performance:

RQ	Metric	Definition	Threshold
RQ1	Drift Detection Recall (DDR)	% of true DRI drift events detected before critical threshold breach	≥ 90%
RQ2	Alert Response Latency (ARL)	Median hours from alert trigger to acknowledged intervention	≤ 4h (automated), ≤ 24h (manual)
RQ3	Component Degradation Rate (CDR)	Max silent degradation in any DRI sub-component over monitoring window	≤ 0.10 per week

Drift Detection Recall measures how often the monitoring system detects a genuine DRI decline (defined as a drop of ≥ 0.10 within any 14-day rolling window) before the portfolio asset crosses the critical threshold of 0.45. False negatives carry asymmetric cost in pharmaceutical contexts — a missed early signal may not be recoverable before a regulatory submission deadline.

Alert Response Latency captures the time elapsed between alert generation and logged acknowledgment by a portfolio manager or automated remediation system. In AI-driven operations, automated responses (data refresh triggers, confidence re-estimation) can eliminate human-in-the-loop latency for routine events while escalating high-severity cases [9]^[10].

Component Degradation Rate monitors whether any single DRI sub-component degrades silently while the aggregate DRI remains above the warning threshold. A composite score can mask component-level failures: a drop in regulatory alignment may be temporarily offset by strong data completeness, delaying detection of a structural problem.

graph LR
    RQ1 --> DDR[Drift Detection Recall\n≥90%] --> EW[Early-warning window\nmeasured in hours]
    RQ2 --> ARL[Alert Response Latency\n≤4h automated] --> OP[Operational pipeline\nbenchmarking]
    RQ3 --> CDR[Component Degradation Rate\n≤0.10 / week] --> CB[Component-level\ndashboard]

Monitoring frequency directly governs DDR. Our simulation uses a 90-day, three-asset pharmaceutical portfolio dataset (see data in GitHub repository) with controlled drift events injected at known timestamps to compute ground-truth detection rates.

4. Application to the HPF-P Case #

4.1 DRI Drift Detection Across Monitoring Frequencies #

Figure 1 (dridriftmonitoring.png) illustrates DRI trajectories for three representative portfolio assets across a 90-day Q1 2026 window. Asset B exhibits a two-stage progressive decline: a first drop at day 40 (DRI falling from 0.58 to 0.38) and a secondary shock at day 55. With weekly monitoring, only the final breach would have been detected. With daily monitoring, the first drift event triggers an alert 14 days earlier, leaving time for data enrichment before the critical zone is reached.

Figure 1. DRI Signal Drift: 3-asset pharmaceutical portfolio over 90 days. Red zone: critical (DRI < 0.45). Orange zone: warning (0.45–0.60). Asset B shows progressive drift requiring early-warning intervention.

Figure 2 quantifies the accuracy–latency tradeoff across five monitoring frequencies. At a 6-hour interval, DDR reaches 94.1% with a latency of 6 hours. Daily monitoring achieves 91.5% DDR — acceptable for most portfolio decisions. Weekly monitoring drops to 83.2% DDR, below our 90% threshold, confirming that sub-daily monitoring is required for HPF-P deployments with active decision pressure.

Figure 2. Detection accuracy (bars) and alert latency (line, log scale) across five monitoring frequencies. Daily monitoring (91.5% DDR, 24h latency) represents the minimum viable configuration for pharmaceutical portfolio use.

4.2 Automated vs Manual Alert Response #

Figure 4 shows the response time distributions for automated pipeline responses versus manual review workflows across 200 simulated portfolio alert events. The automated pipeline achieves a median response of 1.4 hours, with 95% of events addressed within 5 hours. Manual workflows exhibit a long-tail distribution (median 8.3 hours) driven by calendar effects, time-zone handoffs, and the unavoidable latency of human notification chains.

Figure 4. Response time distribution for automated versus manual DRI alert handling. Automated systems reduce median response latency from 8.3h to 1.4h.

For pharmaceutical portfolios, this difference matters most in two scenarios: (a) regulatory submission windows where DRI must be confirmed above threshold before data locks, and (b) partnering negotiations where portfolio readiness signals are shared with external stakeholders. A 6.9-hour median improvement translates into substantial risk reduction across a portfolio of 20+ assets [10]^[11].

The HPF-P framework specifies three automated response tiers for DRI alerts:

• Tier 1 (DRI ≥ 0.60): Logging only, next scheduled refresh proceeds normally.
• Tier 2 (0.45 ≤ DRI < 0.60): Auto-triggered data validation sweep + portfolio manager notification.
• Tier 3 (DRI < 0.45): Immediate decision freeze flag, escalation to senior review, emergency data refresh protocol.

4.3 Component-Level Dashboard and Silent Degradation #

Figure 3 presents the DRI component radar for the three simulated assets at the end of the monitoring period. Asset B’s critical DRI (0.38) decomposes into severe deficits in source timeliness (0.30) and regulatory alignment (0.28) — the two components most sensitive to external information delays. Asset A’s moderate DRI (0.71) masks a weak source timeliness score (0.65) that, if not addressed, could drive the asset toward the warning zone within two refresh cycles.

Figure 3. DRI component radar: data completeness, source timeliness, signal consistency, expert confidence, regulatory alignment. Asset B’s critical DRI traces to source timeliness and regulatory alignment deficits.

Component-level monitoring requires extending the standard DRI scalar into a vector telemetry feed. Each sub-component is tracked independently, with its own control chart and threshold boundaries. This aligns with the AI-driven pharmaceutical supply chain architecture literature, which identifies component-level observability as a prerequisite for root-cause analysis in multi-source decision pipelines [11]^[12].

The Integrating DRI and DRL protocol specifies that when any single component falls below 0.35, the aggregate DRI should be treated as unreliable regardless of its scalar value [9]^[10]. Continuous component monitoring enforces this rule automatically, preventing false confidence from composite score smoothing.

Pharmaceutical AI-driven innovations increasingly rely on real-time operational intelligence as a competitive differentiator [12]^[13]. The pharmaceutical project portfolio optimisation literature confirms that dynamic re-weighting based on continuous signal quality substantially improves expected portfolio value under uncertainty [3]^[4]. HPF-P’s real-time DRI layer operationalises these insights by making monitoring a first-class architectural concern rather than a reporting afterthought.

The regulatory perspective further reinforces this direction: FDA and EMA guidance frameworks for AI/ML in GMP environments expect continuous performance monitoring with defined thresholds, change-management procedures, and audit trails [8]^[9]. HPF-P’s tiered alert architecture directly satisfies these requirements, enabling regulatory compliance to be built into the monitoring layer from day one.

DRI score interpretation must account for Decision Readiness Level (DRL) context: a DRI of 0.68 for an asset at DRL-3 (validated integration) requires different response urgency than the same score at DRL-1 (concept alignment) [13]^[14]. Real-time monitoring systems therefore benefit from DRL-aware thresholds — tightening the early-warning boundary as an asset advances through DRL stages.

5. Conclusion #

RQ1 Finding: Sub-daily monitoring (every 6–24 hours) is necessary to achieve Drift Detection Recall ≥ 90%. Measured by DDR = 91.5% at daily cadence versus 83.2% at weekly cadence. This matters for our series because HPF-P deployments handling active regulatory submission windows cannot tolerate weekly-only monitoring — the operational standard for continuous HPF-P systems is daily refreshes with optional 6-hour windows for high-DRL assets.

RQ2 Finding: Automated alert pipelines reduce median response latency from 8.3 hours (manual) to 1.4 hours, a 5.9× improvement. Measured by Alert Response Latency across 200 simulated portfolio events. This matters for our series because DRI-based decision freezes triggered by automated Tier 3 alerts can prevent irreversible portfolio decisions during data quality crises — a capability not possible with human-only review chains.

RQ3 Finding: Source timeliness and regulatory alignment are the most volatile DRI sub-components, accounting for >60% of silent degradation events in simulated portfolios. Measured by Component Degradation Rate tracking across the five sub-components. This matters for our series because component-level dashboards allow targeted data refresh actions rather than wholesale DRI resets — reducing operational cost while maintaining signal integrity.

The next article in this series examines Regulatory Compliance Integration, addressing how DRL stage-gate milestones align with EMA and FDA submission requirements and how the HPF-P framework ensures that decision readiness certifications are audit-ready from the first DRL stage.